The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients.
M. Pia Morelli
No relevant relationships to disclose
Michael J. Overman
No relevant relationships to disclose
Eduardo Vilar Sanchez
No relevant relationships to disclose
Van Karlyle Morris
No relevant relationships to disclose
Imad Shureiqi
No relevant relationships to disclose
Chris R. Garrett
No relevant relationships to disclose
David R. Fogelman
No relevant relationships to disclose
Kanwal Pratap Singh Raghav
No relevant relationships to disclose
Bryan K. Kee
No relevant relationships to disclose
Laurel Deaton
No relevant relationships to disclose
Cathy Eng
No relevant relationships to disclose
Robert A. Wolff
No relevant relationships to disclose
Dragan Sebisanovic
Employment or Leadership Position - Guardant Health
LaiMun Siew
Employment or Leadership Position - Guardant Health
Aubrey Zapanta
Employment or Leadership Position - Guardant Health
Gangwu Mei
Employment or Leadership Position - Guardant Health
Ben Schiller
Employment or Leadership Position - Guardant Health
Helmy Eltoukhy
Employment or Leadership Position - Guardant Health
AmirAli Talasaz
Employment or Leadership Position - Guardant Health
Scott Kopetz
No relevant relationships to disclose